Research Article
Clinical Significance of OX40 and OX40 Ligand in the Peripheral Blood of Patients with Myasthenia Gravis
Table 6
Clinical characteristics of patients with MG in relapse and remission.
| | Clinical characteristics | Membrane-bound molecules | Soluble molecules | | Remission () | Relapse () | value | Remission () | Relapse () | value |
| | Age (years) | 46.0 (36.0, 58.0) | 48.0 (32.0, 58.0) | 0.754 | 39.0 (34.0, 57.0) | 50.5 (40.0, 62.0) | 0.258 | | Age of onset, (%) | | | | | | | | EOMG () | 17 (40.4) | 12 (54.6) | 0.283 | 19 (63.3) | 16 (47.1) | 0.192 | | LOMG () | 18 (42.9) | 8 (36.4) | 0.192 | 11 (36.7) | 18 (52.9) | | | Sex, (%) | | | 0.557 | | | 0.141 | | Female | 27 (64.3) | 14 (63.6) | | 21 (70.0) | 20 (58.8) | | | Male | 15 (35.7) | 8 (36.4) | | 9 (30.0) | 14 (41.2) | | | MGFA classification, (%) | | | ≤0.001 | | | ≤0.001 | | OMG | 30 (71.4) | 3 (13.6) | | 19 (63.3) | 3 (8.8) | | | GMG | 12 (28.6) | 19 (86.4) | | 11 (36.7) | 31 (91.2) | | | Thymoma, (%) | | | 0.050 | | | 0.011 | | Without | 35 (83.3) | 13 (59.1) | | 21 (70.0) | 13 (38.2) | | | With | 7 (16.7) | 9 (40.9) | | 9 (30.0) | 21 (61.8) | | | AchR-Ab, (%) | | | 0.003 | | | 1.000 | | Positive, (%) | 35 (83.3) | 20 (90.9) | | 30 (100.0) | 34 (100.0) | | | Negative, (%) | 7 (16.7) | 2 (9.1) | | 0 (0.0) | 0 (0.0) | | | QMGs | 7.0 (4.0, 8.0) | 13.0 (11.0, 18.0) | ≤0.001 | 7.0 (6.0, 9.0) | 14.0 (12.0, 20.0) | ≤0.001 | | Treatment, (%) | | | | | | | | Pyridostigmine | 2 (4.8) | 3 (13.6) | 0.329 | 0 (0) | 0 (0) | / | | Glucocorticoid | 18 (42.9) | 10 (45.5) | 1.000 | 15 (50) | 26 (76.5) | 0.218 | | Immunosuppressants | | | | | | | | Azathioprine | 8 (19.0) | 1 (4.5) | 0.147 | 4 (13.3) | 3 (8.8) | 0.679 | | Tacrolimus | 11 (26.2) | 5 (22.7) | 1.000 | 9 (30) | 2 (5.9) | 0.018 | | Mycophenolate mofetil | 1 (2.4) | 2 (9.1) | 0.270 | 0 (0) | 1 (2.9) | 1.000 | | Cyclophosphamide | 2 (4.8) | 1 (4.5) | 1.000 | 2 (6.7) | 2 (5.9) | 1.000 |
|
|
Abbreviations: HC: healthy control; EOMG: early-onset myasthenia gravis; LOMG: late-onset myasthenia gravis; MGFA: Myasthenia Gravis Foundation of America; AchR-Ab: acetylcholine receptor antibodies; QMGs: quantitative myasthenia gravis scores.
|
